Uzbekistan and Kazakhstan Step Up Cooperation in the Field of Pharmacopoeia

Tashkent, Uzbekistan (UzDaily.com) — The Center for Pharmaceutical Product Safety hosted a meeting between representatives of pharmacopoeia authorities from Uzbekistan and Kazakhstan.

From Uzbekistan, the meeting was attended by Professor Khabibulla Jalilov, Head of the State Pharmacopoeia Development Department and Editor-in-Chief of the State Pharmacopoeia, Kamola Nuridullaeva, Chair of the Pharmacopoeia Committee, as well as other specialists of the State Pharmacopoeia.

From Kazakhstan, the delegation was led by Professor Ardak Tulegenova, Head of the Department for the Improvement of the EAEU Pharmacopoeia, Honorary Member of the National Academy of Sciences, Chair of the EAEU Pharmacopoeia Committee and of the State Pharmacopoeia of Kazakhstan.

The sides discussed ways to expand and strengthen cooperation between the pharmacopoeia authorities of both countries.

Particular attention was given to the following areas: harmonization of pharmacopoeia standards within the Eurasian Economic Union (EAEU) and development of unified requirements, knowledge exchange and expanded collaboration, training of qualified specialists, organization of professional development programs and internships, holding scientific and practical seminars and workshops, introduction of international best practices in quality control, provision of methodological support, as well as the integration of digital technologies and innovative methods into pharmacopoeia standards.

At the conclusion of the talks, both sides agreed to further strengthen scientific and technical cooperation in the pharmacopoeia sphere, expand human resource capacity, develop joint programs and courses, and adopt new technologies.

This meeting marks a new stage in strategic cooperation between Uzbekistan and Kazakhstan in the field of pharmacopoeia, contributing to the harmonization of pharmaceutical standards, enhancement of quality and safety control of medicines, and strengthening the two countries’ standing within the global pharmacopoeia community.